{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:13:57Z","timestamp":1793945637039,"version":"4.8.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.intimp.2024.112320","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T01:44:02Z","timestamp":1716515042000},"page":"112320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["mRNA vaccines against infectious diseases and future direction"],"prefix":"10.1016","volume":"135","author":[{"given":"Muhammad Tahir","family":"Aleem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furqan","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Shakoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenfei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2024.112320_b0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/v14020401","article-title":"mRNA vaccine development for emerging animal and zoonotic diseases","volume":"14","author":"Le","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2024.112320_b0010","first-page":"28","article-title":"The deadly hemorrhagic form of smallpox: an epidemic disease in British Colonial India","author":"Shastri","year":"2014","journal-title":"IOSR J. Hum. S Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.112320_b0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2024.112320_b0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112320_b0025","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2024.112320_b0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-4939-6481-9_6","article-title":"Nucleoside modified mRNA vaccines for infectious diseases","volume":"1499","author":"Pardi","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.intimp.2024.112320_b0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.intimp.2024.112320_b0040","first-page":"31","article-title":"Self-amplifying mRNA-based vaccine technology and its mode of action","volume":"440","author":"Maruggi","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112320_b0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/vaccines9020081","article-title":"Development of mRNA vaccines: scientific and regulatory issues","volume":"9","author":"Knezevic","year":"2021","journal-title":"Vaccines (basel)"},{"issue":"4","key":"10.1016\/j.intimp.2024.112320_b0050","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1189\/jlb.1009684","article-title":"IL-23 and IL-12p70 production by monocytes and dendritic cells in primary HIV-1 infection","volume":"87","author":"Louis","year":"2010","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112320_b0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cmi.2012.61","article-title":"TLR signaling in B-cell development and activation","volume":"10","author":"Hua","year":"2013","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112320_b0060","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.immuni.2013.05.007","article-title":"Cytosolic sensing of viruses","volume":"38","author":"Goubau","year":"2013","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.intimp.2024.112320_b0065","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14760584.2017.1355245","article-title":"Mechanism of action of mRNA-based vaccines","volume":"16","author":"Iavarone","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"3","key":"10.1016\/j.intimp.2024.112320_b0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2010.01.020","article-title":"RIG-I detects viral genomic RNA during negative-strand RNA virus infection","volume":"140","author":"Rehwinkel","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.112320_b0075","doi-asserted-by":"crossref","unstructured":"O.A.W. Haabeth, J.J.K. Lohmeyer, A. Sallets, et al., An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory. Preprint. bioRxiv 2021. 04.14.439891. doi:10.1101\/2021.04.14.439891.","DOI":"10.1101\/2021.04.14.439891"},{"issue":"13","key":"10.1016\/j.intimp.2024.112320_b0080","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1084\/jem.20101102","article-title":"Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons","volume":"207","author":"Gregorio","year":"2010","journal-title":"J. Exp. Med."},{"issue":"7522","key":"10.1016\/j.intimp.2024.112320_b0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nature13590","article-title":"Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates","volume":"514","author":"Goubau","year":"2014","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.intimp.2024.112320_b0090","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1074\/jbc.M310175200","article-title":"mRNA is an endogenous ligand for Toll-like receptor 3","volume":"279","author":"Karik\u00f3","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"5\u20136","key":"10.1016\/j.intimp.2024.112320_b0095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000494034","article-title":"Extracellular RNA sensing by pattern recognition receptors","volume":"10","author":"Tatematsu","year":"2018","journal-title":"J. Innate Immun."},{"issue":"11","key":"10.1016\/j.intimp.2024.112320_b0100","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2016.161","article-title":"Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses","volume":"24","author":"De Beuckelaer","year":"2016","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2024.112320_b0110","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.2147\/IDR.S341694","article-title":"The development of mRNA vaccines for infectious diseases: recent updates","volume":"14","author":"Nitika","year":"2021","journal-title":"Infect Drug Resist"},{"issue":"12","key":"10.1016\/j.intimp.2024.112320_b0115","doi-asserted-by":"crossref","first-page":"e0006108","DOI":"10.1371\/journal.pntd.0006108","article-title":"A thermostable messenger RNA based vaccine against rabies","volume":"11","author":"Stitz","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.intimp.2024.112320_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104648","article-title":"Nonclinical safety assessment of repeated administration and biodistribution of a novel rabies self-amplifying mRNA vaccine in rats","volume":"113","author":"Stokes","year":"2020","journal-title":"Regul. Toxicol. Pharm."},{"issue":"3","key":"10.1016\/j.intimp.2024.112320_b0125","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijbiomac.2011.05.015","article-title":"Enhancement of Astragalus polysaccharide on the immune responses in pigs inoculated with foot-and-mouth disease virus vaccine","volume":"49","author":"Li","year":"2011","journal-title":"Int. J. Biol. Macromol."},{"issue":"17","key":"10.1016\/j.intimp.2024.112320_b0130","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1016\/j.vaccine.2006.02.011","article-title":"Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha","volume":"24","author":"de Avila","year":"2006","journal-title":"Vaccine"},{"issue":"2012","key":"10.1016\/j.intimp.2024.112320_b0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4236\/aim.2012.24053","article-title":"Transcriptional expression profile of toll like receptor 1\u201310 mRNA in bovine peripheral mononuclear cells in response to foot and mouth disease antigens","volume":"2012","author":"Gaikwad","year":"2012","journal-title":"Adv. Micro"},{"key":"10.1016\/j.intimp.2024.112320_b0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rvsc.2018.05.017","article-title":"Association of the expression of Th cytokines with peripheral CD4 and CD8 lymphocyte subsets after vaccination with FMD vaccine in Holstein young sires","volume":"119","author":"Yang","year":"2018","journal-title":"Res. Vet. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2024.112320_b0145","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.antiviral.2009.12.005","article-title":"RNA immunization can protect mice against foot-and-mouth disease virus","volume":"85","author":"Pulido","year":"2010","journal-title":"Antiviral Res."},{"issue":"13","key":"10.1016\/j.intimp.2024.112320_b0150","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1128\/JVI.00599-11","article-title":"RNA structural domains in noncoding regions of the foot-and-mouth disease virus genome trigger innate immunity in porcine cells and mice","volume":"85","author":"Rodr\u00edguez-Pulido","year":"2011","journal-title":"J. Virol."},{"issue":"40","key":"10.1016\/j.intimp.2024.112320_b0155","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1016\/j.vaccine.2013.07.008","article-title":"Delivery of synthetic RNA can enhance the immunogenicity of vaccines against foot-and-mouth disease virus (FMDV) in mice","volume":"31","author":"Borrego","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2024.112320_b0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2017.03.009","article-title":"Combined administration of synthetic RNA and a conventional vaccine improves immune responses and protection against foot-and-mouth disease virus in swine","volume":"142","author":"Borrego","year":"2017","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00705-018-4008-2","article-title":"Recombination of host cell mRNA with the Asia 1 foot-and-mouth disease virus genome in cell suspension culture","volume":"164","author":"Zou","year":"2019","journal-title":"Arch. Virol."},{"key":"10.1016\/j.intimp.2024.112320_b0170","unstructured":"F. Munir, R. Asrar, M. Ahsan, A. Asif, A.H. Shah, Rabies: 100 % preventable but remains a daily threat to millions around the world, a comprehensive review, Sci. Res. J. 202 IX. doi: 10.31364\/SCIRJ\/v9.i02.2021.P0221XX."},{"issue":"10101","key":"10.1016\/j.intimp.2024.112320_b0175","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2024.112320_b0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/vaccines7040132","article-title":"Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies","volume":"7","author":"Armbruster","year":"2019","journal-title":"Vaccines (basel)"},{"issue":"6","key":"10.1016\/j.intimp.2024.112320_b0185","doi-asserted-by":"crossref","first-page":"e0004746","DOI":"10.1371\/journal.pntd.0004746","article-title":"An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs","volume":"10","author":"Schnee","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2024.112320_b0190","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/14760584.2021.1990043","article-title":"Overcoming roadblocks in the development of vaccines for leishmaniasis","volume":"20","author":"Kaye","year":"2021","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0195","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s13071-022-05437-x","article-title":"Structural analysis of PpSP15 and PsSP9 sand fly salivary proteins designed with a self-cleavable linker as a live vaccine candidate against cutaneous leishmaniasis","volume":"15","author":"Lajevardi","year":"2022","journal-title":"Parasit. Vectors"},{"issue":"14","key":"10.1016\/j.intimp.2024.112320_b0200","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1017\/S0031182009991156","article-title":"Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis","volume":"136","author":"Quinnell","year":"2009","journal-title":"Parasitology"},{"key":"10.1016\/j.intimp.2024.112320_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.parint.2022.102577","article-title":"An alphavirus-derived self-amplifying mRNA encoding PpSP15-LmSTI1 fusion protein for the design of a vaccine against leishmaniasis","volume":"89","author":"Savar","year":"2022","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.intimp.2024.112320_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2021.101749","article-title":"Quantitative evaluation of PpSP15-LmSTI1 fusion gene expression following transfection with an alphavirus-derived self-amplifying mRNA and conventional DNA vaccine platforms","volume":"59","author":"Savar","year":"2021","journal-title":"Mol. Cell. Probes"},{"key":"10.1016\/j.intimp.2024.112320_b0215","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3389\/fimmu.2018.02420","article-title":"Heterologous immunization with defined RNA and subunit vaccines enhances T cell responses that protect against Leishmania donovani","volume":"9","author":"Duthie","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0220","first-page":"1","article-title":"Flow of zoonotic toxoplasmosis in food chain","volume":"43","author":"Almuzaini","year":"2023","journal-title":"Pak. Vet. J."},{"key":"10.1016\/j.intimp.2024.112320_b0225","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fmicb.2017.00605","article-title":"Induction of protective immunity against Toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP)","volume":"8","author":"Luo","year":"2017","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112320_b0230","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14712598.2018.1413086","article-title":"Moving towards improved vaccines for Toxoplasma gondii","volume":"18","author":"Li","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2024.112320_b0235","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.vaccine.2005.09.053","article-title":"Induction of protective immunity against toxoplasmosis in mice by immunization with Toxoplasma gondii RNA","volume":"24","author":"Dimier-Poisson","year":"2006","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.intimp.2024.112320_b0240","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.intimp.2024.112320_b0245","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/vaccines7030096","article-title":"Immunogenicity and protection efficacy of a naked self-replicating mRNA-based zika virus vaccine","volume":"7","author":"Zhong","year":"2019","journal-title":"Vaccines (basel)"},{"issue":"5","key":"10.1016\/j.intimp.2024.112320_b0250","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"7644","key":"10.1016\/j.intimp.2024.112320_b0255","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","article-title":"An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection","volume":"8","author":"Bollman","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"8","key":"10.1016\/j.intimp.2024.112320_b0265","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3201\/eid1408.080287","article-title":"Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007","volume":"14","author":"Lanciotti","year":"2008","journal-title":"Emerg. Infect. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2024.112320_b0270","doi-asserted-by":"crossref","first-page":"e0004816","DOI":"10.1371\/journal.pntd.0004816","article-title":"Isolation of infective zika virus from urine and saliva of patients in Brazil","volume":"10","author":"Bonaldo","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2024.112320_b0275","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines protect against zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2024.112320_b0280","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/MMBR.69.4.635-664.2005","article-title":"Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus","volume":"69","author":"Weiss","year":"2005","journal-title":"Microbiol Mol Biol Rev"},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2024.112320_b0285","first-page":"S103","article-title":"From SARS coronavirus to novel animal and human coronaviruses","volume":"5","author":"To","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.intimp.2024.112320_b0290","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12985-016-0544-0","article-title":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir","volume":"13","author":"Mohd","year":"2016","journal-title":"Virol. J."},{"issue":"6494","key":"10.1016\/j.intimp.2024.112320_b0295","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2","volume":"368","author":"Shi","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0300","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2024.112320_b0305","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/tbed.13804","article-title":"Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development","volume":"68","author":"Begum","year":"2021","journal-title":"Transbound. Emerg. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0310","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2024.112320_b0315","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ymthe.2021.04.001","article-title":"A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice","volume":"29","author":"de Alwis","year":"2021","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2024.112320_b0320","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.intimp.2024.112320_b0325","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112320_b0330","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112320_b0335","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (basel)"},{"issue":"36","key":"10.1016\/j.intimp.2024.112320_b0340","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"PNAS"},{"issue":"7","key":"10.1016\/j.intimp.2024.112320_b0345","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/CVI.00031-12","article-title":"Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity","volume":"19","author":"Uematsu","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"issue":"46","key":"10.1016\/j.intimp.2024.112320_b0350","doi-asserted-by":"crossref","first-page":"23068","DOI":"10.1073\/pnas.1821754116","article-title":"Pseudouridinylation of mRNA coding sequences alters translation","volume":"116","author":"Eyler","year":"2019","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.intimp.2024.112320_b0355","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112320_b0360","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14760584.2015.986104","article-title":"Lipid-based mRNA vaccine delivery systems","volume":"14","author":"Midoux","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2024.112320_b0365","first-page":"71","article-title":"Formulation and delivery technologies for mRNA vaccines","volume":"440","author":"Zeng","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112320_b0370","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2024.112320_b0375","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0380","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines (basel)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0385","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/22221751.2019.1590128","article-title":"Replication and virulence in pigs of the first African swine fever virus isolated in China","volume":"8","author":"Zhao","year":"2019","journal-title":"Emerg Microbes Infect."},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0390","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40249-018-0495-3","article-title":"African swine fever: an unprecedented disaster and challenge to China","volume":"7","author":"Wang","year":"2018","journal-title":"Infect. Dis. Poverty"},{"issue":"5","key":"10.1016\/j.intimp.2024.112320_b0395","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11427-020-1657-9","article-title":"A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated vaccine in pigs","volume":"63","author":"Chen","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"12","key":"10.1016\/j.intimp.2024.112320_b0400","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/pathogens9121078","article-title":"Computational analysis of African swine fever virus protein space for the design of an epitope-based vaccine ensemble","volume":"9","author":"Ros-Lucas","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.intimp.2024.112320_b0405","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fimmu.2014.00171","article-title":"T cell responses to viral infections \u2013 opportunities for Peptide vaccination","volume":"5","author":"Rosendahl Huber","year":"2014","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112320_b0410","doi-asserted-by":"crossref","first-page":"e0213091","DOI":"10.1371\/journal.pone.0213091","article-title":"Correction: a PRRSV GP5-Mosaic vaccine: Protection of pigs from challenge and ex vivo detection of IFN\u03b3 responses against several genotype 2 strains","volume":"14","author":"Cui","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0415","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/vaccines8010106","article-title":"Broad protection of pigs against heterologous PRRSV strains by a GP5-mosaic DNA vaccine prime\/GP5-mosaic rVaccinia (VACV) vaccine boost","volume":"8","author":"Cui","year":"2020","journal-title":"Vaccines (basel)"},{"issue":"7798","key":"10.1016\/j.intimp.2024.112320_b0420","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"7830","key":"10.1016\/j.intimp.2024.112320_b0425","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2024.112320_b0430","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12033-021-00432-6","article-title":"Bioengineering of novel non-replicating mRNA (NRM) and self-amplifying mRNA (SAM) vaccine candidates against SARS-CoV-2 using immunoinformatics approach","volume":"64","author":"Bhattacharya","year":"2022","journal-title":"Mol. Biotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112320_b0435","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/088282404322875421","article-title":"Induction of T lymphocytes specific for bovine viral diarrhea virus in calves with maternal antibody","volume":"17","author":"Endsley","year":"2004","journal-title":"Viral Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112320_b0440","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/CVI.00415-13","article-title":"Assessment of the phenotype and functionality of porcine CD8 T cell responses following vaccination with live attenuated classical swine fever virus (CSFV) and virulent CSFV challenge","volume":"20","author":"Franzoni","year":"2013","journal-title":"Clin. Vaccine Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924008403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924008403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T08:16:09Z","timestamp":1717661769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924008403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":88,"alternative-id":["S1567576924008403"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112320","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA vaccines against infectious diseases and future direction","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112320"}}